CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
6.60
+0.09 (1.38%)
At close: Dec 5, 2025, 4:00 PM EST
6.55
-0.05 (-0.76%)
After-hours: Dec 5, 2025, 7:09 PM EST
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors.
The company’s drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies.
It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
CNS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | John Climaco |
Contact Details
Address: 2100 West Loop South, Suite 900 Houston, Texas 77027 United States | |
| Phone | 800-946-9185 |
| Website | cnspharma.com |
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H508 |
| ISIN Number | US18978H5081 |
| Employer ID | 82-2318545 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Michael Climaco Esq., J.D. | Chief Executive Officer, President and Director |
| Christopher S. Downs CPA, CTP, FP&A | Chief Financial Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer |
| Dr. Donald H. Picker Ph.D. | Chief Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 4, 2025 | SCHEDULE 13G | Filing |
| Oct 28, 2025 | ARS | Filing |
| Oct 24, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 10, 2025 | PRE 14A | Other preliminary proxy statements |
| Sep 19, 2025 | 424B5 | Filing |
| Aug 14, 2025 | SCHEDULE 13G | Filing |